A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of gefapixant
(MK-7264) in premenopausal female participants with moderate to severe endometriosis-related
pain. The primary hypothesis: gefapixant is superior to placebo in reducing the average daily
pelvic pain score (cyclic and non-cyclic, combined) during Treatment Cycle 2.